Table 1. Clinicopathologic characteristics of the ependymoma samples used in this study.

Sample	Sex	Age atDiagnosis(years)	Tumor Location	Specimen	TreatmentPrior to Surgery	Age at Surgery (years)	WHO Grade*	SpecimenTime toRelapse(years)	Patient Status	Follow-up(years)*
1A	F	8.2	ST	Recurrent	RT	17.2	II	0.9	DOD	10.6
1B	F	8.2	ST	Recurrent	C/RT	18.1	II	0.2	DOD	10.6
2	M	7.0	IT	Recurrent	RT	16.2	II	0.6	DOD	10.0
3A	F	16.4	ST	Primary	None	16.4	III	0.4	NED	8.8+
3B	F	16.4	ST	Recurrent	None	16.8	III	1.5	NED	8.8+
3C	F	16.4	ST	Recurrent	RT	18.3	II	NR	NED	8.8+
4A	M	1.2	IT	Recurrent	C	6.2	III	1.2	DOD	11.2
4B	M	1.2	IT	Recurrent	C	7.5	II	1.7	DOD	11.2
5	M	2.2	ST	Recurrent	None	3.9	II	NR	NED	13.4+
6A	F	9.2	IT	Recurrent	C/RT	13.2	II	0.5	DOD	6.8
6B	F	9.2	IT	Recurrent	C/RT	13.8	II	1.1	DOD	6.8
6C	F	9.2	IT	Recurrent	C/RT	14.9	II	0.8	DOD	6.8
7	F	7.6	IT	Primary	None	7.6	II	1.2	DOD	2.4
8	F	9.7	IT	Recurrent	C/RT	14.6	II	NR	NED	13.1+
9	M	5.2	IT	Recurrent	C/RT	6.6	II	2.2	NED	7.1+
10	F	0.2	IT	Primary	None	0.2	III	0.6	DOD	0.6
11	M	0.9	IT	Primary	None	0.9	II	1.0	DOD	7.1
12A	F	1.1	IT	Primary	None	1.1	III	1.8	DOD	4.0
12B	F	1.1	IT	Recurrent	C/RT	3.0	III	0.2	DOD	4.0
12C	F	1.1	IT	Recurrent	C/RT	4.5	III	0.3	DOD	4.0
13	F	6.3	ST	Recurrent	None	8.1	III	1.2	NED	10.7+
14	F	15.4	IT	Primary	None	15.4	II	0.3	DOD	2.5
15	F	1.9	IT	Primary	None	1.9	III	0.4	DOD	0.5
16	M	4.1	IT	Recurrent	C/RT	11.0	III	0.2	AWD	10.3+
17	M	1.3	IT	Primary	None	1.3	II	1.2	DOD	1.4
18	F	11.1	IT	Primary	None	11.1	II	NR	NED	8.4+
19	F	1.4	IT	Primary	None	1.5	II	NR	NED	8.4+
20	M	5.8	IT	Primary	None	5.8	II	2.5	DOD	3.4
21	M	12.8	IT	Recurrent	RT	14.5	II	0.8	DOD	3.5
22	M	0.8	IT	Primary	None	0.8	II	1.0	DOD	6.8
23	M	0.8	IT	Recurrent	C/RT	5.8	II	0.9	DOD	6.8
24	M	2.5	IT	Recurrent	C/RT	11.4	II	1.0	DOD	11.0
25	F	11.1	ST	Primary	None	11.1	III	NR	NED	6.4+
26	F	5.2	IT	Primary	None	5.2	III	NR	NED	4.9+

Abbreviations: IT, Infratentorial; ST, Supratentorial; C, Chemotherapy treatment; RT, Radiotherapy treatment; NR, No Relapse to date; AWD, Alive With Disease; NED, No Evidence of Disease; DOD, Dead as a result Of the Disease;

*Based on standard WHO (World Health Organization) classification for ependymomas.

Note: The letters represent different samples from the same patient.